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L IVER transplantation has been increasingly used to treat end-stage liver diseases since the introduction 
of Cy A in combination with other immunosuppressive 
agents. 1 Although Cy A has a powerful immunosuppres-
sive effect on allograft rejection, many transplant recipi-
ents still experience rejection episodes that are often 
irreversible. The nephrotoxicity of Cy A in some recipients 
has necessitated the reduction of CyA dosage below 
effective levels. With liver recipients refractory to conven-
tional immunosuppression or with CyA-induced nephro-
toxicity, a first-phase clinical trial of a new immunosuppres-
sive drug, FK 506. has been initiated at our institution. Z 
FK 506 was shown by in vitro and in vivo studies to be 
considerably more immunosuppressive than CyA. J•7 The 
successful outcome of the initial clinical studies on 14 liver 
transplant recipients2 has led to a formal clinical trial of FK 
506 as the primary immunosuppressive agent in combina-
tion with low doses of steroids.8 
Appropriate dosages of FK 506 are being determined to 
provide optimal immunosuppression without significant 
adverse side effects. The monitoring of blood levels of FK 
506 is essential in these studies. This monitoring has 
become possible with an enzyme immunoassay (ELISA) 
using anti-FK 506 MoAbs. This assay was developed by 
Tamura et al9 and modified by Cadoff et al. 10 
FK 506 is a highly lipophilic macrolide (molecular 
weight 822). II Although little is known about the metabo-
lites of FK 506, recent studies have implicated the liver as 
the primary site of FK 506 metabolism. 12 
The objective of this study was to determine the rela-
tionship between plasma levels of FK 506 as measured by 
ELISA and by a bioassay based on the proliferative 
response of an alloreactive T cell line. 
MATERIALS AND METHODS 
Plasma 
Five milliliters of heparinized blood was collected from four liver 
transplant recipients during lhe lirst month following transplanta· 
tion. Each sample was drawn Just prior to FK 506 administration. 
All blood samples were incubated at 37"C for I hour prior to 
centrifugation. The plasma was analyzed for FK 506 trough levels 
using an indirect ELISA 10 and a bioassay described in detail 
below. 
Drug Source 
FK 506 was supplied in crystalline form by the Fujisawa Pharma-
ceutical Co Ltd. Osaka. Japan. A stock solution of 100 !L8iml FK 
506 was prepared in methanol and kept at -4°C. 
Bioassay of FK 506 Levels in Plasma 
Inhibition Effect of FK 506 on Lymphocyte Proliferation. This 
was determined in a secondary proliferation assay using a DQwI-
specific alloreactive T cell clone 082913 as responder cells. 
Frozen cloned cells were thawed and washed in RPM I 1640 
(Gibcol and resuspended at 10-' cells/ml in tissue culture medium 
(TCM) consisting of RPMI 1640 supplemented with 25 mmoVL 
Hepes buffer. 100 U/ml gentamicin. and 10% nontransfused 
human male serum. The inhibitory effect of FK 506 on the primed 
lymphocyte (PLTI response of D829 cells was measured at 
different concentrations of the drug. ranging from 0.003- t nglml. 
In these 3-day PL T assays. 10' responder cells were incubated in 
triplicate with IW DQw I-positive stimulator cells irradiated (2.000 
rad) in 200 IA-i of TCM. During the final 20 hours of incubation. 
each culture was labeled with IILCi ofJH-thymidine. The cultures 
were harvested and counted in a liquid scintillation counter 
(LKB). The inhibitory effect of FK 506 at various concentrations 
was determined with the following formula: 
( cpm with drug ) percent inhibition = I -. x 100 
cpm wtthout drug 
Effect of Plasma Samples on Lymphocyte Proliferation. 
Plasma samples were diluted (V2 to V .. ) in TCM. The inhibitory 
effect of different plasma dilutions on the PL T response of 0829 
cells was measured as described for FK 506. In these assays. 10" 
responder cells (50 IA-il and 10-' stimulator cells (50 IA-i) were 
incubated with 100 ILl of plasma. A pretransplant plasma sample 
from each patient was used as a control. The results were 
calculated with the following formula: 
percent mhibition in plasma 
= I - x 100 ( cpm with test PlaSma) 
cpm control plasma, 
Calculation of FK 506 Levels From Bioassay Results. The 
plasma concentrations of FK 506 were calculated from the inhi-
bition curve observed with various plasma dilutions in comparison 
with a standard curve for FK 506. These calculations were made 
using a nonlinear sigmoidal model curve litting program (Statisti-
cal Analysis System ISASllnstitute. release 5.18. Cary. Nc). The 
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IC50 from the standard curve was determined as the concentration 
of FK 506 (ng/m!) which caused 50% inhibition of the PLT 
response of 0829. From the plasma Inhibition curve. the 10'0 was 
determined as the dilution factor for which plasma induced 50% 
inhibition of PLT response of 0829. From these values. the 
plasma concentration of FK 506 was calculated as fC~o x 1050, 
RESULTS 
Initial studies showed highly consistent dose response 
curves of PLT inhibition of D829 celis by FK 506. Fig 1 
shows representative results of three separate experi-
ments. These data yielded a mean fC~o value of 0.063 :!: 
0.001 ngtmi. 
Examples of PLT inhibition of D829 by patient plasma 
are shown in Table I. These bioassays were done on a liver 
allograft recipient at 7. 12. and 14 days posttransplant. The 
plasma FK 506 levels were calculated by multiplying the 
fa~o values with the fC~o value of 0.063 nglml. 
Companson Between FK 506 Levels Measured by ELISA 
and Bioassay 
In all plasma samples tested. the values for FK 506 levels 
obtained by ELISA were generally much higher than those 
determined in the bioassay. Fig 2 compares FK 506 levels 
determined by ELISA and bioassay for two liver trans-
plant recipients. 
Patient P2 was originally diagnosed with sclerosing 
cholangitis and had lost five previous liver allografts while 
on CyA treatment. Following the sixth transplant. 6 mgld 
of FK 506 was administered intravenously for 7 days. 
Methylprednisolone (I g) was given on the second day 
posttransplant and was tapered daily to a maintenance 
dose of 10-20 mgld. Although FK 506 levels determined by 
bioassay were always lower than those measured in 
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Fig 1. Standard curves of the FK 506 bioassay. The concentra-
tion of FK 506 is plotted versus percent inhibition of PL T response 
of DB29 cells. The ICso was calculated uSIng a nonlinear sigmoIdal 
model fitted to the points. 
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Table 1. Bioassay of FK 506 Levels In Plasma From a Liver 
Transplant Recipient 
Dilutions ("to Inhibitionl 
FK 506t 
Days Posttransolanl 1:4 1:8 1:16 1:32 ID",' (ng/mll 
7 99 89 48 0 15 0.94 
12 93 40 0 0 7 0.44 
14 99 98 76 16 21 1.32 
'ID5O represents the plasma dilUtion factor causing 50"1. inhibition of PLT 
response of DB29 cells. 
tCalculated trv multiplying ID", by \he IC50 of 0.063 nglml. 
ELISA (0.2-2 nglml versus 0.5-4.5 nglm!). they showed a 
significant correlation (P < 0.001. r = 0.77). 
Following the first bolus of methylprednisolone (day 2 
postsurgeryl, the FK 506 concentrations measured by 
ELISA were four- to fivefold higher than the bioassay 
levels. FK 506 was discontinued for 4 days; the ELISA 
concentrations of FK 506 dropped sharply to 0.5-1 nglml. 
and no detectable immunosuppressive activity was found 
in the bioassay in those plasma samples. On day II 
postsurgery. the patient showed clinical symptoms of graft 
dysfunction as determined by changes in liver enzymes. 
On the same day. FK 506 (6 mgld) and a bolus of 
methylprednisolone (I g) were administered. Conse-
quently. there was a rapid increase in the ELISA plasma 
concentrations of FK 506 and a more gradual rise in the 
bioassay-determined FK 506 levels (Fig 2a). 
Similar findings are shown for patient P14. who was 
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Fig 2. FK 506 levels In plasma measured by the bioassay and by 
the ELISA for lIver transplant patIents. (a) P2 and (b) P14. 
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diagnosed with hepatitis B and juvenile diabetes mellitus. 
He received kidney, pancreas. and liver allografts. FK 506 
(4.5 mg) was administered intravenously two times per 
day, and this dose was maintained for 19 days posttrans-
plantation. Steroids were given on days 2, 5, and 19 
post surgery . 
A significant correlation (P < 0.001. r = 0.75) was 
found between the two assays for plasma levels of FK 506 
(Fig 2b). 
Following steroid administration, FK 506 levels deter-
mined by bioassay were still much lower than ELISA 
plasma concentrations of FK 506, 
Relationship Between FK 506 Dose and the Plasma 
Concentration 
There was no apparent correlation between the dose of FK 
506 given and the concentration of FK 506 in the patient's 
plasma. Although patients P14. P16. and P32 received the 
same dose of FK 506. the plasma levels of FK 506 (ELISA 
and bioassay) were much higher in patients PI4 and PI6 
than in the patient P32 (Fig 2 and Table 2). Furthermore. in 
three of four plasma samples tested from patient P32. the 
bioassay levels of FK 506 were <0.1 ng/ml. whereas the 
ELISA values ranged from 0.3-\.6 ng/ml. This patient had 
a histologically confinned cellular rejection. Patient P16. 
on a similar dose of FK 506. had a stable posttransplant 
course. His plasma concentrations of FK 506 as deter-
mined by ELISA and bioassay were 1.2-6 ng/ml and 1-4 
ng/ml. respectively. 
DISCUSSION 
This study was designed to assess the correlation between 
FK 506 levels measured by bioassay and ELISA. 
The bioassay was based on the inhibition of PL T reac-
tivity of an alloreactive T cell clone. Low concentrations 
of FK 506 significantly inhibited the proliferative re-
sponses of mixed lymphocyte reaction (MLRl-derived 
Table 2. Correlation Between Blo .... y .nd ELISA 
Drug Dose 
Days PosttranSJ)lant (mglday) 
Patient P32 
2 4.5 x 2 IV" 
5 4.5 x 2 IV" 
8 9 x 2 PDt 
12 9 x 2 PDt 
Patient P16 
2 9 x 2 PDt 
3 9 x 2 PDt 
4 9 x 2 PDt 
5 9 x 2 PDt 
6 9 x 2 PDt 
7 9 x 2 POt 
'Intravenous dose 01 4 5 mg FK S06 twice • day. 
tOraI dose 01 9 ITIgId twICe • day. 
Bioassay 
(ng/mI) 
< 0.1 
1.7 
< 0.06 
< 0.06 
2.4 
1.7 
1.0 
1.3 
·4 
2.5 
ELISA 
Ing/ml) 
1.6 
6.4 
0.9 
0.3 
2.6 
2.3 
1.2 
1.8 
6 
3 
ZEEVI, EIRAS, BURCKART ET AL 
alloreactive T cell clones! and this inhibition was repro-
ducible when the same T cell line was used (Fig I), The 
sensitivity of the ELISA for FK 506 was 0.1 ng/ml lo 
whereas in the bioassay. drug levels of 0.063 :!: 0.001 ng/ml 
had a significant inhibitory effect on the responder cells, 
The levels of FK 506 determined in bioassay were 
consistently lower than those measured by ELISA. This 
suggests that the blood may contain inactive metabolites of 
FK 506 which could be detected by the ELISA. Since the 
ELISA is an immunoassay, it may measure biologically 
active and non-active metabolites that might cross-react 
with the anti-FK 506 antibody. Similarly. Cy A metabolites 
are measured by monoclonal and polyclonal radioimmu-
noassay (RIA )used for monitoring trough levels ofCyA in 
transplant recipients. 14 
FK 506-treated patients received a bolus of high-dose 
steroids the second day posttransplant and when acute 
allograft rejection was suspected. Steroids could affect the 
determination of FK 506 levels by the bioassay since this 
assay does not discriminate between various Immunosup-
pressive drugs. Nevertheless. the FK 506 levels measured 
by bioassay poststeroid treatment were not much affected 
in contrast to the marked increases in immunoassayed FK 
506. It is unclear how steroids influence ELISA assay. 
Corticosteroids have been shown to be inducers of hepatic 
drug metabolism. 12 Experience with CyA immunosuppres-
sion has demonstrated that RIA levels of CyA increased 
after steroid treatment while high-pressure liquid chroma-
tography-measured CyA levels appeared unatfectedKl~ 
Further studies are needed to elucidate the potential effect 
of steroids on FK 506 metabolism. 
Biologic assays have previously been used for the mea-
surement of CyA in patient's plasma based on the inhibi-
tion by the plasma of a third-party MLR. No attempt was 
made. however. to express the inhibitory activity as a 
concentration of biologically active CyA. Both Kahan l4 
and Reisman et al lo suggested that biologic assay has 
clinical relevance: patients with continually low plasma 
immunosuppressive activity are prone to rejection of their 
kidney allografts. Our preliminary observations also indi-
cated that the absence of immunosuppressive activity in 
patient's plasma was associated with liver allograft rejec-
tion (patient P321. 
Recently. Jain et al 17 have shown that moderate to 
severe hepatic dysfunction induced an increase in trough 
levels of FK 506 measured by ELISA. Also. the Cy A RIA 
levels were higher than the specific measurements of Cy A 
during rejection episodes following liver transplantation. 1M 
Studies are currently in progress to analyze the relation-
ship between ELISA and bioassay levels during acute 
allograft rejection. 
In conclusion, a bioassay based on the inhibition of an 
alloreactive T cell clone proliferation was used to deter-
mine FK 506 levels in patient's plasma. A positive corre-
lation was demonstrated between drug levels measured by 
the bioassay and ELISA. However, the FK 506 levels 
were lower for the bioassav than for ELISA. Since FK 506 
FK 506 BIOASSAY IN TRANSPLANT PATIENTS 
cannot yet be assayed accurately in plasma using specific 
chromatographic techniques. the bioassay is important for 
assisting in the interpretation of an immunoassay (ELISA) 
with unknown specificity for biologically non-active forms 
of FK 506. Furthennore. biologic assay may be useful for 
patient management if active metabolites are induced. or 
to detect the interaction between FK 506 and other drugs 
(high-dose steroids) in the immunosuppression of allograft 
rejection. 
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